Peter Attia MD
No clinically validated dose exists, as these are clinical practice patterns, not trial-tested protocols
HUBERMAN: Well, the first relates to something that many people take BPC-157 for because they believe it's good for them, and in some cases, potentially could be, which is that in addition to increasing fibroblast migration and angiogenesis, blood vessel development within a site of injury, BPC-157 is known to have a small but nonetheless meaningful impact on upregulating growth hormone receptors
The effects of B12 injections may last several weeks , with maintenance treatments recommended for continued benefits
GLP1s, peptides, NAD, and regenerative techniques can be transformative when used thoughtfully
\n\n\n\n Unlike many pharmacological agents, BPC-157 does not appear to bind exclusively to a single receptor